January 17, 2025 07:00 AM ESTUpdated 10:15 AM

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze “late last year,” the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

Ozempic makes list for next round of Medicare drug price negotiations

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

AstraZeneca wins BTK race to market in first-line mantle cell lymphoma

After three-month delay, Amgen’s Lumakras clinches FDA green light in colorectal cancer

Broad Institute paper offers potential new framework for treating Huntington’s disease

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Copy Chief

Editor

Sign up to read this article for free.

more like this

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down